For example, in triple-negative breast cancer (TNBC), NAT10 enhances JunB mRNA stability through ac4C modification, drives the upregulation of LDHA expression, promotes glycolysis and lactate accumulation, inhibits T-cell activation and accelerates tumor progression, whereas the NAT10 inhibitor Remodelin reduces LDHA expression, remodels the tumor microenvironment, and effectively inhibits tumor growth and lung metastasis. Here, NAT10 is linked to neoplasm.